BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
See today's BioWorld
Home
» Idenix, GSK Team Up in $450M HIV Deal
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Idenix, GSK Team Up in $450M HIV Deal
Feb. 9, 2009
By
Catherine Hollingsworth
No Comments
Idenix Pharmaceuticals Inc. has granted London-based GlaxoSmithKline plc worldwide rights to IDX899, a potential treatment for HIV/AIDS, in a deal that could bring in a potential $450 million for the U.S-based biotech. (BioWorld Today)
BioWorld